Services
Company
Legal and Governance
Publication Library / Publications
Modern chemotherapy management of recurrent ovarian cancer: a multicentre study
Aims
The natural history of ovarian cancer has changed over the last 10 years due to more effective drug treatments. The aim of this multicentre audit of the management of recurrent ovarian cancer was to examine the usage of newer drugs in light of the publication of National Institute of Clinical Excellence guidance.
Materials and methods
All patients presenting with a first or subsequent relapse of ovarian cancer between August 2001 and February 2003 in nine UK National Health Service centres were identified. Data were recorded retrospectively and prospectively from point of entry into the study and included the modality of primary cancer treatment, the treatment of each subsequent relapse and outcome.
Results
In total, 245 evaluable patients were entered on to the database. The mean age was 62 years. All patients received a platinum-based chemotherapy regimen as first-line treatment. One hundred and fifty-five patients (63%) went on to receive third-line chemotherapy and 82 (34%) received fourth-line chemotherapy. The median survival from first relapse was estimated to be in excess of 12 months from our data. The efficacies of the chemotherapy agents used are comparable with the results of published phase III trials.
Conclusion
This study shows that multicentre audit is feasible and provides useful information on current clinical practice on which to base future research.
Authors
S Chan, M Griffin, J Stewart, K Gregory, A Hughes, S Awwad, R Allerton, S Pledge, H Thomas, F Percival, Ovarian Cancer Audit Group UK
Journal
Clinical Oncology
Therapeutic Area
Oncology
Center of Excellence
Real-world Evidence & Data Analytics
Year
2007
Read full article